A Randomised, Double-blind, Placebo-controlled, Dose-finding Study Evaluating Efficacy, Safety, and Tolerability of Different Oral Doses of BI 1819479 Over at Least 24 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 02 Jun 2025
At a glance
- Drugs BI 1819479 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 16 May 2025 Status changed from recruiting to active, no longer recruiting.
- 16 Apr 2025 Planned End Date changed from 21 Jul 2026 to 3 Feb 2026.
- 16 Apr 2025 Planned primary completion date changed from 21 May 2026 to 3 Dec 2025.